Filing Overview
Cellyan Biotechnology Co., Ltd., a foreign private issuer filing under Form 20-F, furnished this Form 6-K for September 2026. The report was signed on September 23, 2026, and describes board and committee changes effective September 18, 2026.
Business Context and Reporting Period
The filing concerns the resignation of an independent director and the appointment of his replacement. It does not provide operating or financial results for the month or any other reporting period.
Key Financial Metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: the filing text does not provide clear values.
Material Changes
- Mike Yao Zhou resigned from the Board, the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as chairperson of the Compensation Committee, effective September 18, 2026.
- Letao Zhao was appointed as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective September 18, 2026.
- Mr. Zhao has more than 20 years of reported entrepreneurial and operational experience in retail apparel, restaurant operations, store management, strategic planning, and brand development.
- The filing states that Mr. Zhao has no family relationship with any director or executive officer and had no transaction with the Company during the preceding two years requiring disclosure under Item 404(a) of Regulation S-K.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance, business outlook, risk-factor update, contingency, or unusual financial item is disclosed.
- The report is incorporated by reference into the Company’s Form S-8 registration statement (File No. 333-298301) and Form F-3 registration statement (File No. 333-296754), except to the extent superseded by later filings.
Investor Verification Points
- Confirm the effective date and scope of Mr. Zhao’s independent-director and committee appointments.
- Review subsequent filings for any changes to the Board, committee composition, or director independence.
- Consult the Company’s latest Form 20-F and other filings for financial performance, liquidity, debt, operating risks, and forward-looking information, none of which is provided in this Form 6-K.